anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a drug delivery system having a micelle structure including a PEG_(2000)-DSPE polymerized lipid and an APT_(EDB)-PEG_(2000)-DSPE polymer, and a method for producing the same. The drug delivery system targets extradomain B of fibronectin (EDB-FN), which is overexpressed in brain tumors, and passes through a blood-brain barrier (BBB) or a blood-brain tumor barrier (BBTB). Thus, drugs can be delivered specifically to brain tumor cells. In addition, the present invention can provide a pharmaceutical composition for brain tumor diagnosis or treatment comprising the drug-loaded drug delivery system as an active ingredient. The composition accumulates inside the brain tumor and is entrapped into the tumor cells to specifically inhibit tumor growth. The present invention may be usefully used for diagnosis or treatment of brain tumors.
INTRODUCTION: Pain management is essential in the immediate post-surgical period. We sought to describe the ketorolac dose regimen in neonates and infants following cardiac surgery. Secondary outcomes included renal dysfunction, bleeding, and pain management.
METHODS: We performed a single-centre retrospective cohort study of neonates and infants (aged < 12 months) who received ketorolac following cardiac surgery, from November 2020 through November 2021 (inclusive). Ketorolac was administered at 0.5 mg/kg every 6 hours. Safety was defined by absence of a clinically significant decline in renal function (i.e., increase in serum creatinine [SCr] by ≥ 0.3 mg/dL from baseline within 48 hours and/or urine output ≤ 0.5 mL/kg/hour for 6 hours) and absence of clinically significant bleeding defined as major by International Society on Thrombosis and Hemostasis paediatric criteria or Severe/Fatal Bleeding Events by Nellis et al. Efficacy measures included pain scores and opioid utilisation.
RESULTS: Fifty-five patients met eligibility criteria. The median (range) dose and duration of ketorolac administration was 0.5 mg/kg/dose for 48 (6-90) hours. Among all patients, there was not a statistically significant difference observed in median SCr within 48 hours of baseline (p > .9). There were no major or severe bleeding events. The median (range) opioid requirements (morphine intravenous equivalents per kg per day) at 48 hours post-ketorolac initiation was 0.1 (0-0.8) mg/kg/day.
CONCLUSIONS: If validated prospectively, these findings suggest that a ketorolac regimen 0.5 mg/kg/dose every 6 hours in neonates and infants post-cardiac surgery may be safe with regard to renal function and bleeding risk, and effective regarding opioid-sparing capacity.
The present invention relates to a pharmaceutical composition for preventing and treating dysmenorrhea and preterm labor, comprising a non-polar solvent fraction of a ginger extract as an effective component. The present invention relates to a pharmaceutical composition for preventing and treating dysmenorrhea or preterm labor, comprising a non-polar fraction of ginger as an effective component. The non-polar fraction of ginger according to the present invention has an excellent effect at suppressing voluntary or drug-induced contraction of uterine smooth muscle, and thus may be beneficially used in the prevention and treatment of dysmenorrhea or preterm labor. Additionally, products using ginger powder and extracts are being sold worldwide, and these products are known for being favorably received by users, while only minor adverse reactions are intermittently reported associated with its long-term use. Additionally, there has been no reported increase in pattern or frequency of unusual adverse reactions from using ginger as compared to the placebo control group. Ginger, when orally administered, has high clearance rate while the main components of ginger, shogaol or gingerol are absorbed 90% or more without accumulating in the body, and thus is considered safe even when repeatedly administered within the recommended allowance of a commercial product.
An anticancer sustained-release injection is provided, which contains tumor multidrug resistance reversal agent and cytotoxic drugs. The anticancer sustained-release injection comprises sustained-release microspheres and solvents, wherein the sustained-release microspheres contain anticancer active components and sustained-release adjuvant, and the solvents are special solvents containing a suspending agent. The anticancer active components comprise a tumor multidrug resistance reversal agent selected from nelarabine, zarnestra, ropinirole and valspodar and/or a cytotoxic drug selected from cyclophosphamide, carmustine, nimustine, camptothecin, paclitaxel, cisplatin, carboplatin, vincristine, buthionine sulfoximine, O6-benzyladenine and O4-benzyl folic acid. The sustained-release adjuvant is selected from polifeprosan, di-fatty acid-decanedioic acid copolymer, polylactic acid and EVAc. The suspending agent has a viscocity of 100-3000 cp (25-30 DEG C) and is preferably sodium carboxymethylcellulose. The sustained-release microspheres can also be formulated as sustained-release implants or gel injections for injection or implantation in tumors or around tumors, to inhibit tumor cells and selectively enhance the therapeutic effect of nonoperative treatment such as chemotherapy.
OBJECTIVES: Cerebral Small Vessel Disease (CSVD) is a chronic, progressive vascular disorder that confers increased vulnerability to psychiatric syndromes, including late-life mood disorders. In this study, we investigated the impact of CSVD on electroconvulsive therapy (ECT) outcomes in patients with late-onset bipolar disorder (BD).
METHODS: A sample of 54 non-demented elderly patients (≥60 years) with late-onset BD and treatment-resistant major depression, mixed state, or catatonia who underwent bilateral ECT were included in this naturalistic observational study. A diagnosis of CSVD was established based on brain neuroimaging performed before ECT. All patients were evaluated before and after ECT using the Brief Psychiatric Rating Scale (BPRS), the Hamilton Rating Scale for Depression (HAM-D), and the Clinical Global Impression scale (CGI).
RESULTS: Of the total sample, 19 patients were diagnosed with CSVD (35.2%). No significant differences were observed at baseline between patients with and without CSVD. Overall, a response was obtained in 66%-68.5% of patients, with remission in 56.2%. No significant differences in ECT outcomes were found between those with and without CSVD, and both groups exhibited substantial improvements in symptom severity following ECT.
CONCLUSIONS: The outcome of ECT in late-onset BD was not influenced by the presence of CSVD. This finding aligns with previous research on unipolar depression. Accordingly, ECT should be considered for elderly patients with late-onset BD, regardless of the presence of CSVD.
Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
A biologically-active compound which includes an inorganic mixed metal cationic portion having anion exchange properties and an anionic portion containing a biologically-active anion. The mixed metal cationic portion can be an oxide, hydroxide, or both, and can be fully hydrated, partially hydrated, or not hydrated. The biologically-active anion can be, e.g., an antibiotic, an analgesic, an antimicrobial, a pharmaceutical, an antioxidant, or an agricultural chemical such as a herbicide or a pesticide. These biologically-active compounds can have controlled-release properties and can be produced by relatively simple processes, using for the cationic portion relatively common starting materials. These biologically-active compounds are useful, for example, in compositions to form pharmaceuticals, antioxidants, or herbicides, and can be incorporated into a polymeric material to form a shaped body, such as a plastic film which can be utilized to form bags for food storage or transportation. Also included are processes for making the biologically-active compounds.
Identifying and targeting microenvironment-driven pathways that are active across acute myeloid leukemia (AML) genetic subtypes should allow the development of more broadly effective therapies. The proinflammatory cytokine interleukin-1β (IL-1β) is abundant in the AML microenvironment and promotes leukemic growth. Through RNA-sequencing analysis, we identify that IL-1β-upregulated ASF1B (antisilencing function-1B), a histone chaperone, in AML progenitors compared with healthy progenitors. ASF1B, along with its paralogous protein ASF1A, recruits H3-H4 histones onto the replication fork during S-phase, a process regulated by Tousled-like kinase 1 and 2 (TLKs). Although ASF1s and TLKs are known to be overexpressed in multiple solid tumors and associated with poor prognosis, their functional roles in hematopoiesis and inflammation-driven leukemia remain unexplored. In this study, we identify that ASF1s and TLKs are overexpressed in multiple genetic subtypes of AML. We demonstrate that depletion of ASF1s significantly reduces leukemic cell growth in both in vitro and in vivo models using human cells. Using a murine model, we show that overexpression of ASF1B accelerates leukemia progression. Moreover, Asf1b or Tlk2 deletion delayed leukemia progression, whereas these proteins are dispensable for normal hematopoiesis. Through proteomics and phosphoproteomics analyses, we uncover that the TLK-ASF1 pathway promotes leukemogenesis by affecting the cell cycle and DNA damage pathways. Collectively, our findings identify the TLK1-ASF1 pathway as a novel mediator of inflammatory signaling and a promising therapeutic target for AML treatment across diverse genetic subtypes. Selective inhibition of this pathway offers potential opportunities to intervene effectively, address intratumoral heterogeneity, and ultimately improve clinical outcomes in AML.
Repeated hypoxic episodes can produce a sustained (>60 min) increase in neural drive to the diaphragm. The requirement of repeated hypoxic episodes (vs. a single episode) to produce phrenic motor facilitation (pMF) can be removed by allosteric modulation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors using ampakines. We hypothesized that the ampakine-hypoxia interaction resulting in pMF requires that ampakine dosing precedes the onset of hypoxia. Phrenic nerve recordings were made from urethane-anesthetized, mechanically ventilated, and vagotomized adult male Sprague-Dawley rats during isocapnic conditions. Ampakine CX717 (15 mg/kg iv) was given immediately before (n = 8), during (n = 8), or immediately after (n = 8) a 5-min hypoxic episode (arterial oxygen partial pressure 40-45 mmHg). Ampakine before hypoxia (Aprior) resulted in a sustained increase in inspiratory phrenic burst amplitude (i.e., pMF) reaching +70 ± 21% above baseline (BL) after 60 min. This was considerably greater than corresponding values in the groups receiving ampakine during hypoxia (+28 ± 47% above BL, P = 0.005 vs. Aprior) or after hypoxia (+23 ± 40% above BL, P = 0.005 vs. Aprior). Phrenic inspiratory burst rate, heart rate, and systolic, diastolic, and mean arterial pressure (mmHg) were similar across the three treatment groups (all P > 0.3, treatment effect). We conclude that the presentation order of ampakine and hypoxia impacts the magnitude of pMF, with ampakine pretreatment evoking the strongest response. Ampakine pretreatment may have value in the context of hypoxia-based neurorehabilitation strategies.NEW & NOTEWORTHY Phrenic motor facilitation (pMF) is evoked after repeated episodes of brief hypoxia. pMF can also be induced when an allosteric modulator of AMPA receptors (ampakine) is intravenously delivered immediately before a single brief hypoxic episode. Here we show that ampakine delivery before hypoxia (vs. during or after hypoxia) evokes the largest pMF with minimal impact on arterial blood pressure and heart rate. Ampakine pretreatment may have value in the context of hypoxia-based neurorehabilitation strategies.
PURPOSE:To obtain a cosmetic capable of effectively manifesting the action of a plant extract without deteriorating the quality by appearance due to no initial coloring and discoloration with time by blending the plant extract. CONSTITUTION:This cosmetic comprises (A) a plant extract, e.g. an extract solution of a plant, e.g. Aloe, Puerariae Radix, Caryophylli Flos, Perillae Folium, Thea sinensis L. (green tea), Scutellariae Radix, Mori Cortex or Glycyrrhiziae Radix and (B) sulfurous acid or its salts, e.g. sodium hydrogensulfite or potassium sulfite. The blending amounts of the respective ingredients are within the range of preferably 0.001-10wt.%, especially preferably 0.01-5wt.% dry weight of the ingredient (A) based on the total composition and within the range of preferably 0.1-100wt.%, especially preferably 1-10wt.% dry weight of the ingredient (B) based on the ingredient (A). Furthermore, an aqueous ingredient, a powdery ingredient, a surfactant, a humectant ingredient, a thickening agent, an oil, pH adjustor, a perfume, etc., can be blended in the cosmetic.
BACKGROUND: Hepatocellular carcinoma (HCC) remains a formidable challenge in oncology, with its pathogenesis and progression influenced by myriad factors. Among them, the pervasive organic synthetic compound, bisphenol A (BPA), previously linked with various adverse health effects, has been speculated to play a role. This study endeavors to elucidate the complex interplay between BPA, the immune microenvironment of HCC, and the broader molecular landscape of this malignancy.
METHODS: A comprehensive analysis was undertaken using data procured from both The Cancer Genome Atlas and the Comparative Toxicogenomics Database. Rigorous differential expression analyses were executed, supplemented by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. In addition, single-sample gene set enrichment analysis, gene set enrichment analysis and gene set variation analysis were employed to reveal potential molecular links and insights. Immune infiltration patterns were delineated, and a series of in vitro experiments on HCC cells were conducted to directly assess the impact of BPA exposure.
RESULTS: Our findings unveiled a diverse array of active immune cells and functions within HCC. Distinct correlations emerged between high-immune-related scores, established markers of the tumor microenvironment and the expression of immune checkpoint genes. A significant discovery was the identification of key genes simultaneously associated with immune-related pathways and BPA exposure. Leveraging these genes, a prognostic model was crafted, offering predictive insights into HCC patient outcomes. Intriguingly, in vitro studies suggested that BPA exposure could promote proliferation in HCC cells.
CONCLUSION: This research underscores the multifaceted nature of HCC's immune microenvironment and sheds light on BPA's potential modulatory effects therein. The constructed prognostic model, if validated further, could serve as a robust tool for risk stratification in HCC, potentially guiding therapeutic strategies. Furthermore, the implications of the findings for immunotherapy are profound, suggesting new avenues for enhancing treatment efficacy. As the battle against HCC continues, understanding of environmental modulators like BPA becomes increasingly pivotal.
Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) play fundamental roles in stem/progenitor cell expansion during homeostasis, and their dysregulation often leads to tissue overgrowth. Here, we show that YAP activation is sufficient to overcome the restriction of global protein synthesis induced by serum starvation, enabling cells to sustain proliferation and survival despite an unfavorable environment. Mechanistically, YAP/TAZ selectively promoted the mTORC1-dependent translation of mRNAs containing 5' terminal oligopyrimidine (5'TOP) motifs, ultimately increasing the cellular polysome content. Interestingly, DNA damage-inducible transcript 4 (DDIT4), a negative regulator of mTORC1, was upregulated by serum starvation but repressed by YAP/TAZ. DDIT4 was sufficient to suppress the translation and transformative potential of uveal melanoma cells, which are often serum unresponsive due to G protein mutations. Our findings reveal a vital role for protein synthesis as a key modality of YAP/TAZ-induced oncogenic transformation and indicate the potential for targeting mTORC1 or translation to treat YAP/TAZ-driven malignancies.
Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
The invention relates to the field of bacteria detection, and provides a photo-thermal method for rapidly and specifically detecting and killing bacteria. The gold nanoparticles functionalized by the nucleic acid aptamer are in a dispersion state with low photothermal conversion effect in the presence of a certain amount of sodium chloride. When salmonella typhimurium exists in the detection environment, the aptamer specifically recognizes and binds to the bacteria, gold nanoparticles are not protected any more, and the gold nanoparticles are in an aggregation state with a high photothermal conversion effect under the induction of sodium chloride. With the increase of the bacterial quantity, the aggregation degree of gold nano particles is increased continuously, the temperature is also increased continuously under the irradiation of laser, and the rapid identification and detection of salmonella typhimurium can be realized within 1 hour by monitoring the temperature difference change through a thermometer. The detection linear range is 10  2 -10 7  CFU/mL, and the detection limit is 49 CFU/mL. In addition, the high temperature brought by the aggregated gold nanoparticles can generate a high-efficiency sterilization effect, and can effectively prevent secondary pollution of samples and medical wastes.
PURPOSE: Eye plaque brachytherapy (EPBT) is the most common treatment for uveal melanoma with high local control rates of 95-100%. When local recurrences occur following EPBT, salvage options include enucleation, transpupillary thermotherapy (TTT), external beam radiation, or re-irradiation with EPBT. The purpose of this study is to report our institution's experience with EPBT re-irradiation for locally recurrent uveal melanoma.
METHODS AND MATERIALS: Patients were included if they were previously treated for uveal melanoma with EPBT, experienced local recurrence, and were subsequently treated at our institution with EPBT from 2016- 2020.
RESULTS: A total of 5 patients with median age 68 years were included. All patients were initially treated at an outside institution (OSI) with Iodine-125 or Ruthenium-106 EPBT. Mean time between EPBT at the OSI and EPBT at our facility was 130 months (range 28-231 months). Patients were re-irradiated with Iodine-125 EPBT prescribed to 85 Gy over 168 hours. Median follow up after re-treatment at our center was 24 months. Local control among this cohort was 100%. Metastasis occurred in two patients after re-treatment, at 8 months and 7 months. At last follow up, all treated lesions were decreased in size. Four patients experienced worsening visual acuity. Four patients developed cataracts, while two patients developed radiation retinopathy with cystoid macular edema requiring anti-VEGF injections. One patient developed radiation retinopathy but did not require injections. No patients required enucleation.
CONCLUSIONS: Re-treatment of locally recurrent uveal melanomas with EPBT is a feasible alternative to enucleation with a high local control rate. Ocular toxicities have not been significant enough to require enucleation.
Ischemic stroke is the most common neurological disease. The main treatment options include medication and endovascular thrombectomy. The benefits of treatments at acute stage are significant but far from satisfactory. There is no effective treatment for improvement at chronic stage, except traditional rehabilitation. In addition, stroke may induce post-stroke autonomic imbalance, further leading to worse post-stroke functional outcomes and the risk of recurrent stroke.

Except for pharmacological therapy against the risk of stroke, non-pharmacological neuromodulation may be proposed as another therapeutic options. Transcutaneous auricular vagus nerve stimulation (VNS) and focused transcranial direct current stimulation (tDCS) may be two of the options. The function of VNS is to modulate post-stroke tissue injury and promote angiogenesis/neurogenesis through non-pharmacological pathway. VNS may increase the parasympathetic activity for balancing the hyper-sympathetic state in the acute stage and enhancing neural plasticity in the chronic stage. On the other hand, the purpose of tDCS is to make substantial motor learning improvements, which may be through the re-balance both excitatory and inhibitory activation between hemispheres after stroke.
During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb. Each activity will be performed for 4 min, with a 1 min preparation time between tasks.